StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.50−0.78 (-7.59%)

Close on Nov 16, 2026Market cap $611.37MP/E –Yield –

Cullinan Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Cullinan Therapeutics's pe ratio was 8.5× on Jul 31, 2023.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jul 31, 20238.5×+3.7
2022Dec 30, 20224.8×–

More Cullinan Therapeutics figures

See a number that looks wrong?